Mian is professor of surgery in the division of urology at Albany Medical College in New York.
Study: Lower PCSM is seen with radical prostatectomy vs other modalities
"This large registry study with data from varied practice settings, incorporating the most commonly used treatment modalities, provides useful data on the long-term mortality outcomes," writes Badar M. Mian, MD.
fPSA: A valuable, inexpensive, and underutilized prostate cancer marker
"FPSA is an important, inexpensive, and readily available test in our risk-stratification toolbox," writes Badar M. Mian, MD.
Biopsy of small renal mass may help avoid unnecessary treatment
"To avoid unnecessary treatment, percutaneous biopsy of the small renal mass has increased for the past several years, but its use remains highly variable," writes Badar M. Mian, MD.
Monitoring, feedback, and financial incentives improve uptake of active surveillance
"The study demonstrated that AS rate in the MUSIC cohort, which in 2014 had been lower than in the SEER cohort, increased rapidly, from approximately 20% in 2014 to nearly 50% in 2019, whereas the SEER cohort showed only a modest increase," writes Badar M. Mian, MD.
Intravesical gemcitabine/docetaxel for NMIBC appears safe and efficacious
The current study is welcome news as it lends further support to the use of intravesical Gem/Doce as a safe and effective option that has the potential to become a new standard of care for high-risk NMIBC.
Prostate focal therapy is feasible and safe but lacks defined indications
"It will only be when the indications for focal therapy are expanded to higher-grade and larger tumors that we will begin to learn about the true efficacy of this approach," writes Badar M. Mian, MD.
Can systematic prostate biopsy be omitted in most men?
"It’s apparent that reducing overdiagnosis alone may not necessarily reduce over treatment, and that separate and specific focus on prevention of over treatment is still needed," Badar M. Mian, MD, writes.
Nephrectomy shows benefit in mRCC managed with systemic therapy
"Up-front CN is associated with a survival benefit in selected patients with mRCC treated with either targeted therapy or ICI therapy," writes Badar M. Mian, MD.
Consider financial toxicity when recommending novel hormonal therapies for prostate cancer
"Ultimately, it will be the treating physician’s responsibility to identify cost-effective alternatives and available resources to help mitigate the financial toxicity incurred from novel cancer therapies," writes Badar M. Mian, MD.
Do 5-ARIs protect against death from prostate cancer?
"It is evident...that the safety of 5-ARIs as it relates to prostate cancer outcomes is contingent upon the clinician understanding its effect on PSA level and making appropriate adjustments to ensure timely deployment of diagnostic imaging and biopsy," writes Badar M. Mian, MD.
Robotic cystectomy is effective, but overall clinical impact is uncertain
Randomized controlled trial compares intracorporeal robotic technique with open surgery.
RP appears more effective against high-risk prostate cancer
"It’s very possible that the PSA screening-detected high-risk prostate cancer portends a more favorable outlook when compared with the pre-PSA era, regardless of the type of primary therapy utilized," writes Badar M. Mian, MD.
Findings support safety, feasibility of partial-gland treatment
"If adequate cancer control can be achieved by focal or partial-gland treatment, then the favorable adverse event profile could make this a preferred option for a number of men with localized intermediate-risk (and possibly selected high-risk) prostate cancer," writes Badar M. Mian, MD.
Unexpected increase in PSA testing after USPSTF recommendations
"It is worth remembering that injudicious use of PSA test, and the downstream consequences of overtreatment and complications, can obscure the benefits associated with PSA-based early detection of prostate cancer," writes Badar M. Mian, MD.
Transrectal vs transperineal biopsy: Comparable outcomes and QoL
"It appears that the TR and TP biopsy procedures are essentially comparable in various aspects of the procedure," writes Badar M. Mian, MD.
Patient-reported HRQOL is maintained after cystectomy
"This study provides credible support for the expectation that post-RC HRQOL should recover and improve over the first 2 years after RC, and provides a benchmark for comparisons with future bladder preservation strategies," writes Badar M. Mian, MD.
Active surveillance for prostate cancer is generally safe, study results show
"This large cohort study confirms the safety of AS, as shown in the low rate of metastasis or death, including those who subsequently converted to treatment," writes Badar M. Mian, MD.
Postprostatectomy radiation dose and timing affect quality of life
"It is apparent from the results of these 2 studies that neither the higher-dose RT nor early RT after RP provide sufficient oncological benefits to justify the adverse impact on functional outcomes and HRQOL," writes Badar M. Mian, MD.
Improved survival is found in mCRPC after PSMA-targeted therapy
"The use of 177Lu-PSMA-617 significantly extended both the imaging-based survival and overall survival," writes Badar M. Mian, MD.
QOL after bladder cancer treatment vs other cancers
"This study provides important and clinically useful information that can be used to plan the intensity of treatment and counsel our patients regarding the cancer-related and QOL-related outcomes after treatment," writes Badar M. Mian, MD.
A tale of 2 lymph node dissections for prostate cancer
"Three decades into prostate-specific antigen screening–detected prostate cancer, the prognostic and therapeutic impacts of various types of pelvic lymph node dissection remain unclear," writes Badar M. Mian, MD.
Prostate cancer functional and oncological outcomes vary among surgeons
The trend persists even after adjusting for surgical volume and experience.
Urologists must remain vigilant regarding post-BCG infection
"It is essential for us to be vigilant about all the complications, whether local or systemic, associated with intravesical BCG," writes Badar M. Mian, MD.
Extended pelvic lymph node dissection during RP does not appear beneficial
The technique fails to demonstrate benefits for prostate cancer recurrence and metastases.
Active surveillance data in prostate cancer show frequent upgrading, rare mortality
"Despite some heterogeneity in the type and frequency of testing during the surveillance period, these results provide reassurance and increased confidence in the safe utilization of AS protocols for men with low-risk GG1, and selected GG2, prostate cancer," Mian writes.
Adjuvant RT after prostatectomy does not improve recurrence rate
PSA monitoring and early salvage therapy appear to be safest in these patients.
Neuropsychiatric effects of ADT often overlooked
Cognitive screening is recommended in patients receiving androgen-deprivation therapy.
Similar outcomes observed with immediate vs delayed radical prostatectomy
Survival outcomes are not compromised in men undergoing active surveillance, a recent study finds.
Quality performance initiative may improve TURBT outcomes in bladder cancer
Increased usage of bladder diagrams was observed following implementation of the program.
Relugolix emerges as "exciting" new treatment in prostate cancer
Dr. Badar M. Mian highlights the safety and efficacy of relugolix, describing the drug as an “exciting new option” for patients with recurrent or advanced prostate cancer.
2 Clarke Drive Cranbury, NJ 08512